Two Sigma Advisers’s Mentari Therapeutics, Inc. Common Stock MTRI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
– Sell
-10
Closed -$23K – 2642
2022
Q2
$23K Sell
10
-21
-68% -$80.3K ﹤0.01% 2541
2022
Q1
$146K Sell
31
-10
-24% -$52.5K ﹤0.01% 2438
2021
Q4
$270K Buy
+41
New +$317K ﹤0.01% 2173

Other funds holding MTRI

Two Sigma Advisers's MTRI Position: Q3 2022 in Review

Two Sigma Advisers sold out of Mentari Therapeutics, Inc. Common Stock (MTRI) in Q3 2022, closing a stake of 10 shares — an estimated $23K sold.

Two Sigma Advisers first reported a position in MTRI in Q4 2021 and held it in 3 quarters. The position peaked at $270K in Q4 2021. 7 funds tracked by Wall St. Rank hold MTRI as of Q3 2022.

  • Two Sigma Advisers reported no remaining Mentari Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Two Sigma Advisers sold 10 Mentari Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $23K.
  • Two Sigma Advisers first reported a position in Mentari Therapeutics, Inc. Common Stock in Q4 2021 and held it in 3 quarters.
  • Two Sigma Advisers's Mentari Therapeutics, Inc. Common Stock position peaked at $270K in Q4 2021.
  • 7 funds tracked by Wall St. Rank held Mentari Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Two Sigma Advisers's 13F filing for Q3 2022, filed 14 Nov 2022.